DEST.L

Destiny Pharma Plc
Destiny Pharma PLC - Director/PDMR Shareholding
5th August 2024, 10:58
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2126Z
Destiny Pharma PLC
05 August 2024
 

Destiny Pharma plc

("Destiny Pharma" or "the Company") 

Director/PDMR Shareholding

Brighton, United Kingdom - 5 August 2024 - Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life-threatening infections, announces that it was notified on 2 August 2024 that on that same day, Sir Nigel Rudd, Chairman of the Company, purchased 1,240,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 2.5 pence.

Following this purchase, Sir Nigel Rudd's beneficial interest in the Company (together with his spouse) is 3,761,716 Ordinary Shares, representing 3.93 per cent of the total issued share capital.

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com

 

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

destinypharma@fticonsulting.com

 

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

  

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US. 

 

For further information on the company, please visit www.destinypharma.com

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sir Nigel Rudd

2.               

Reason for the Notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 1 pence each

Identification code

DEST      GB00BDHSP575

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 2.5 pence

 1,240,000 Ordinary Shares

d)

Aggregated information:

Aggregated volume

Price

 

See 4c) above 

 

e)

Date of the transaction

2 August 2024

f)

Place of the transaction

London Stock Exchange, AIM market (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFEITDIEIIS]]>
TwitterFacebookLinkedIn